Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 55: 1415-1418, 2009. First published May 7, 2009; 10.1373/clinchem.2009.124958
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2009.124958v1
55/7/1415    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ganesamoorthy, D.
Right arrow Articles by Slater, H. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganesamoorthy, D.
Right arrow Articles by Slater, H. R.
(Clinical Chemistry. 2009;55:1415-1418.)
© 2009 American Association for Clinical Chemistry, Inc.


Brief Communication

Development of a Multiplex Ligation-Dependent Probe Amplification Assay for Diagnosis and Estimation of the Frequency of Spinocerebellar Ataxia Type 15

Devika Ganesamoorthy1, Damien L. Bruno1, Jacqueline Schoumans2, Elsdon Storey3, Martin B. Delatycki4, Danqing Zhu5, Morgan K. Wei5, Garth A. Nicholson5, R.J. McKinlay Gardner4 and Howard R. Slater1,4,a

1 Victorian Clinical Genetic Services and Murdoch Children’s Research Institute, University of Melbourne, Department of Paediatrics, Royal Children’s Hospital, Parkville, Victoria, Australia;2 Department of Molecular Medicine and Surgery, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden;3 Department of Medicine, Alfred Hospital, Monash University, Melbourne, Australia;4 Genetic Health Services Victoria, Melbourne, Australia;5 ANZAC Research Institute, University of Sydney, Department of Medicine, Concord Hospital, Sydney, Australia;

aaddress correspondence to this author at: VCGS Cytogenetics Laboratory, Royal Children’s Hospital, Parkville VIC 3052, Australia. Fax +61-3- 83416366; e-mail howard.slater{at}ghsv.org.au.


Abstract

Background: Spinocerebellar ataxia type 15 (SCA15) is a slowly progressive neurodegenerative disorder characterized by cerebellar ataxia. Mutation of the ITPR1 gene (inositol 1,4,5-triphosphate receptor, type 1) has been identified recently as the underlying cause, and in most cases the molecular defect is a multiexon deletion. To date, 5 different SCA15 families have been identified with ITPR1 gene deletion.

Methods: We have designed a synthetic, dual-color multiplex ligation-dependent probe amplification (MLPA) assay that measures copy number with high precision in selected exons across the entire length of ITPR1 and the proximal region of the neighboring gene, SUMF1 (sulfatase modifying factor 1). We screened 189 idiopathic ataxic patients with this MLPA assay.

Results: We identified ITPR1 deletion of exons 1–10 in the previously reported AUS1 family (4 members) and deletion of exons 1–38 in a new family (2 members). In addition to the multiexon deletions, apparent single-exon deletions identified in 2 other patients were subsequently shown to be due to single-nucleotide changes at the ligation sites.

Conclusions: The frequency of ITPR1 deletions is 2.7% in known familial cases. This finding suggests that SCA15 is one of the "less common" SCAs. Although the deletions in the 5 families identified worldwide thus far have been of differing sizes, all share deletion of exons 1–10. This region may be important, both in terms of the underlying pathogenetic mechanism and as a pragmatic target for an accurate, robust, and cost-effective diagnostic analysis.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.